[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590730":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":40,"locations":49,"responsibleParty":65,"collaborators":67,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":78,"minAge":79,"maxAge":80,"enrollmentInfo":81,"targetDuration":29,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":51,"whyStopped":29,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":106},{"fullName":5,"class":6},"Haukeland University Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Nicotinamide Riboside (NR)","EXPERIMENTAL","Nicotinamide Riboside (NR) administered in doses of 1000 mg twice daily for the duration of the trial (8 weeks).",[13],"Dietary Supplement: Nicotinamide Riboside (NR)",{"label":15,"type":6,"description":16,"interventionNames":17},"Placebo","Placebo, no active ingredients. Administered in tablet form twice daily for the duration of the trial (8 weeks).",[18],"Other: Placebo",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DIETARY_SUPPLEMENT","2000 mg NR daily.",[9],[25],"Nicotinamide adenine dinucleotide (NAD)",{"type":6,"name":15,"description":27,"armGroupLabels":28,"otherNames":29},"Placebo tablet identical in taste, shape and appearance to NR tablets.",[15],null,[31,34,38],{"name":32,"affiliation":5,"role":33},"Charalampos Tzoulis, PhD","STUDY_DIRECTOR",{"name":35,"affiliation":36,"role":37},"Katarina Lundervold, MD","University of Bergen","PRINCIPAL_INVESTIGATOR",{"name":39,"affiliation":36,"role":37},"Janne Grønli, PhD",[41,46],{"name":32,"role":42,"phone":43,"phoneExt":44,"email":45},"CONTACT","55975061","47","charalampos.tzoulis@helse-bergen.no",{"name":35,"role":42,"phone":47,"phoneExt":44,"email":48},"55975045","neurosysmedstudier@helse-bergen.no",[50],{"facility":5,"status":51,"city":52,"state":29,"zip":29,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Bergen","Norway","NO",{"type":56,"coordinates":57},"Point",[58,59],5.32415,60.39299,{"lat":59,"lon":58},[62,64],{"name":35,"role":42,"phone":47,"phoneExt":63,"email":48},"+47",{"name":35,"role":37,"phone":29,"phoneExt":29,"email":29},{"type":66,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[68],{"name":36,"class":6},"100590730","phase-2-nadream-effects-of-nicotinamide-adenine-dinucleotide-supplementation-on-sleep-quality-in-healthy-individuals-100590730",false,"NCT06971224","NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals","NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals: A Randomized Controlled Pilot Study","NADream","Inclusion Criteria:\n\n* Participant must be 40 to 60 years of age inclusive, at the time of signing the informed consent.\n* Male or female.\n* Participants who are healthy as determined by medical evaluation including medical history and physical examination.\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the study protocol.\n* Self-reported normal sleep patterns, assessed by Pittsburgh sleep quality index (PSQI; cutoff ≤ 5).\n* No current use of sleep medications or supplements.\n* Able to wear polysomnographic equipment and actigraphy during nighttime.\n\nExclusion Criteria:\n\n* History of sleep disorders (e.g. insomnia, sleep apnea).\n* Abnormal findings on PSG, such as sleep related breathing disorders (apnea-hypopnea index (AHI) ≥ 5), sleep related movement disorders (periodic limb movement index (PLMI) ≥ 15, and parasomnias (like REM sleep behavior disorder (RBD)).\n* Chronic use of alcohol, tobacco, or medications affecting sleep.\n* Significant psychiatric or medical conditions (including neurological, heart, lung, or sleep disorders\u002Fdiseases).\n* Travelled \\>1 time zone and night work \\\u003C1 month before study, or during the study.\n* Extreme chronotype according to the Composite Morningness Questionnaire (evening type; \\\u003C22 and morning type \\>44).\n* Pregnancy.\n* Breastfeeding.\n* Supplements resulting in \\> 20 mg daily of nicotinamide riboside, nicotinamide mononucleotide (NMN), niacin (vitamin B3, nicotinic acid amide or other vitamin B3 analogues) less than 3 months prior to randomization.\n* Participation in other clinical trials last 3 months.\n* Deemed ineligible by lead principal investigator.",true,"ALL","40 Years","60 Years",{"count":82,"type":83},16,"ESTIMATED","INTERVENTIONAL",[86],"PHASE2","The purpose of this study is to evalue the effects of nicotinamide adenine dinucleotide (NAD) supplementation (nicotinamide riboside (NR) form) on sleep in healthy adults compared to a placebo. NAD is important for brain health and energy balance and a proposed explanation for its effect on sleep is that NAD supplementation restores the neurophysiological capacity of the brain to 'rest' during sleep. If this is the case, we expect the administration to result in improvements in sleep quality (and most likely sleep quantity) compared to placebo. Participants will receive either NAD supplementation or a placebo and their sleep will be measured to detect any differences between the two groups.",[89],"Sleep",[89,91,92,93,94,95,96],"Nicotinamide Riboside","NR","Nicotinamide adenine dinucleotide","NAD","Polysomonography","PSG","2025-09-09",{"date":99,"type":100},"2025-09-15","ACTUAL",{"date":102,"type":83},"2025-10-13",{"date":104,"type":83},"2026-06-01",{"name":5,"class":6},1]